Preclinical studies of the FDA-approved drugs for AD such as acetylcholinesterase inhibitors and NMDA antagonists can reduce cognitive decline and levels of amyloid-β protein in AD animal models [66]. This evidence concerns the gene ACHE and Alzheimer disease.